Denmark allows unapproved pill for at-risk Covid-19 patients in line with EMA advice

The European Medicines Agency has issued advice pertaining to the emergency use of the unapproved MSD's Covid-19 tablet treatment, Lagevrio (molnupiravir) – the Danish Health Authority is now allowing treatment with the drug in Denmark.

Photo: MSD / PR

The Danish Health Authority is now allowing Danish doctors to use MSD's tablet treatment, Lagevrio (molnupiravir), to treat Covid-19 patients, despite the drug having yet to be formally approved by the European Medicines Agency (EMA), the Danish authority reports in a press release.

"We recommend the tablet treatment because we have assessed that the benefits outweigh the risks for patients risking severe Covid-19 infections. We expect the treatment will contribute to reducing the number of at-risk patients being hospitalized," MD at Danish Health Authority Kirstine Moll Harboe says in the press release, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs